Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
Trial details
- Registry ID
- NCT03059992
- Drugs studied
- Ibrexafungerp
TrialRedline tracks 7 clinical trials sponsored by Scynexis, Inc.: 5 Phase 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal TreatmentNCT03059992 | Ibrexafungerp | Completed | 2023-08-25Actual |
| Ibrexafungerp for the Treatment of Complicated Vulvovaginal CandidiasisNCT05399641 | Ibrexafungerp | Completed | 2023-05-16Actual |
| Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)NCT03363841 | SCY-078 | Completed | 2023-04-14Actual |
| Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)NCT04029116 | Fluconazole Tablet, IBREXAFUNGERP | Completed | 2021-09-01Actual |
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral FluconazoleNCT05178862 | Echinocandin, Fluconazole, SCY-078 | Terminated | 2025-11-07Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive CandidiasisNCT02244606 | Fluconazole, Micafungin, SCY-078 | Completed | 2016-06Actual |
| Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary AspergillosisNCT03672292 | SCY-078, Voriconazole | Terminated | 2023-03-27Actual |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: All-cause mortality (US FDA Only) Measure: Global Response at End of Treatment (EU European Medicines Agency [EMA] Only). After: Measure: All-cause Mortality Measure: Global Response at End of Treatment (EU European Medicines Agency [EMA] Only).
Before: Estimated. After: Actual.
Before: 31 Dec 2026. After: 7 Nov 2025.
Before: Active not recruiting. After: Terminated.